Loading data for IGC — first visit, this takes a few seconds.
IGC Pharma Inc. (IGC)
NYSE American: IGC
· Real-Time Price · USD
0.30
-0.01 (-3.23%)
At close: Aug 24, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
IGC Pharma Inc. (IGC) Stock Price, Analysis & Data
-3.23% (1D)
No data available
| Bid | 0.3 |
| Market Cap | 31.08M |
| Revenue (ttm) | 1.11M |
| Net Income (ttm) | -6.45M |
| 0.46 | |
| -0.06 | |
| n/a | |
| -3.54 | |
| P/B (ttm) | 5.01 |
| P/S (ttm) | 28.10 |
| Earnings Date | n/a |
| Ask | 0.3 |
| Volume | 913,476 |
| Avg. Volume (20D) | 619,625 |
| Open | 0.31 |
| Previous Close | 0.31 |
| Day's Range | 0.30 - 0.31 |
| 52-Week Range | 0.24 - 0.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IGC
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheim...
Industry Biotechnology
Sector Healthcare
IPO Date May 24, 2006
Employees 70
Stock Exchange NYSE American
Ticker Symbol IGC
Website https://igcpharma.com
Financial Performance
In 2025, IGC Pharma's revenue was 1.27M, a decrease of -5.5% compared to the previous year's 1.34M. Earnings were -7.12M, a decrease of -45.22%.
Financial StatementsEarnings Surprise
IGC Pharma has released their quarterly earnings on Aug 14, 2026:
- Revenue of $317K misses estimates by $0, with -3.94% YoY decline.
- EPS of -0.03 misses estimates by -0.01, with -50.00% YoY decline.
Page 1 of 2